Important Dates
Abstract submission: Open
Registration opens: August 15, 2018
Early bird registration: Open
On spot registration: March 28, 2019
13th Global Pharmacovigilance & Clinical Trials Summit is organized to start on 28 Mar and end on 29 Mar 2019.
Global Pharmacovigilance 2019 will be held in Osaka, Japan. The Summit location is Hyatt Regency Osaka.
Bringing industry and academia together, 13th Global Pharmacovigilance & Clinical Trials Summit is a 2 days event on Clinical Trials, Pharmacovigilance, Drug Safety and Drug Reactions issues. It also suggests you the opportunity for face-to-face cooperation with those leading the future.
13th Global Pharmacovigilance & Clinical Trials Summit is an annual Summit.
The organizer of the Global Pharmacovigilance 2019, 13th Global Pharmacovigilance & Clinical Trials Summit is Conference Series LLC.
Let Osaka must do attractions make you fall in love with this city when you are there for Global Pharmacovigilance 2019. Here are the top notch things to do in Osaka!
With the grand success of Pharmacovigilance Series of Conferences in UK, USA in consecutive years over the last several years which met with great achievement in Business Conferencing. It’s glad to announce 13th Global Pharmacovigilance & Drug Safety Summit during March 28-29, 2019 Osaka, Japan with the theme “Explore the emerging tools for process automation in pharmacovigilance”. This is a 2 day Mega Event offering Exhibition, at venue to showcase the new and emerging technologies with Keynote presentation, Oral, YRF (Student Presentation), poster, e-poster Presentations.
We are glad to inform you that the Speaker/Delegate/Exhibitor opportunities are available at the conference. Please visit the following link, to know more about the scientific sessions and abstracts submission,
Abstract submission: Open
Registration opens: August 15, 2018
Early bird registration: Open
On spot registration: March 28, 2019
Address : 1 Chome-13-11 Nankokita, Suminoe Ward, Osaka, Osaka Prefecture 559-0034, Japan
Official Site
Report Error
Leave Your Comment